Non-erythroid heme biosynthesis gene, ALAS1, up-regulation after hypomethylating agents predict better outcome in patients with myelodysplastic syndrome

<p>Supplementary Figure:&nbsp;mRNA next generation sequence analysis. (A) mRNA expression of MDS patients treated with AZA. MDS001: MDS with early AZA treatment failure. MDS001_1: before AZA treatment; MDS001_2: under AZA treatment, with response; MDS001_3: AZA treatment failure with leukemia change. MDS002: AZA failure within 2 years. MDS002_1: before treatment; MDS002_2: under AZA treatment, with response. MDS003: long-term AZA treatment response; MDS001: MDS001-1+MDS001-2+MDS001-3. MDS002: MDS002-1 + MDS002-2. MDS003 is MDS003-1</p>